A microneedle-based, integrated smart patch for continuous biomarker monitoring

A. Bocchino¹, E. Melnik², S. Kurzhals², G. C. Mutinati², A. Felice³, C. Hambeck⁴, T. Herndl⁴, P. Donovan⁵, C. O'Mahony¹

¹ Tyndall National Institute, University College Cork, Ireland. ³ DirectSens GmbH, Muthgasse 11/2, 1190 Vienna, Austria.


² AIT Austrian Institute of Technology GmbH, Center for Health and Bioresources, Molecular Diagnostics, Giefinggasse 4, 1210 Vienna, Austria.

⁴ Infineon Technologies, Babenbergerstrasse 10, 8020 Graz, Austria. ⁵ Sanmina Corporation, Fermoy, Cork, Ireland.



Why Monitoring...


- Diabetes, cardiovascular diseases and high blood pressure have a tremendous social cost.
- Evidence-based support is key to decrease their occurrence.
- Molecular biomarkers are the best predictors to use as support.
- Interstitial Fluid (ISF) is rich in biomarkers and easy to access.
- Microneedles (MNs) offer a pain-free option for IF monitoring.





The ELSAH Project...

- Consortium of several research institutes together with small, medium and large enterprises.
- Goal to integrate MNs technology in a smart, patchbased wearable sensor system.
- monitoring lactate continuous functionalising the MNs.
- Exploitation plan to bring the patch to the market.









Control

- ARcare

-PMMA


- Varnish

Scan me!

Amperometric detection


Dispensed surface modification developed by AIT to functionalise

hundreds of sensors.



Conclusions...

- <u>Scalable</u> production process for the entire system developed.
- Coin-like device: Glucose and Lactate continuous detection built.
- In-human 30 volunteers study performed at Medical University of Graz.
- Tested for cytotoxicity, skin sensitization and skin irritation (ISO10993-5/-10/-23 standards).



EDOT:PSS(-DET



This work was funded by the European Union's Horizon 2020 research and innovation programme under grant #825549 (ELSAH project).















mechanism

